<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04507503</url>
  </required_header>
  <id_info>
    <org_study_id>TAS-120-401</org_study_id>
    <nct_id>NCT04507503</nct_id>
  </id_info>
  <brief_title>Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements</brief_title>
  <official_title>An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <brief_summary>
    <textblock>
      The objective of the study is to provide access to TAS-120 to patients With Advanced&#xD;
      Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study to provide expanded access to TAS-120 prior to its commercial&#xD;
      availability for patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene&#xD;
      Rearrangements who have failed standard therapy or who are unable to tolerate standard&#xD;
      therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Advanced Cholangiocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-120</intervention_name>
    <description>Futibatinib 20mg QD orally on a 28 days cycle</description>
    <other_name>Futibatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent.&#xD;
&#xD;
          2. &gt;18 years of age.&#xD;
&#xD;
          3. Histologically confirmed, locally advanced, or metastatic, or recurrent unresectable&#xD;
             CCA harboring FGFR2 gene rearrangements based on testing performed by a qualified&#xD;
             (CLIA-certified) laboratory.&#xD;
&#xD;
          4. Patient has failed standard therapy or standard therapy is not tolerated.&#xD;
&#xD;
          5. Has measurable or non-measurable lesion(s).&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          7. Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus&#xD;
             homeostasis.&#xD;
&#xD;
          2. History and/or current evidence of clinically significant ectopic&#xD;
             mineralization/calcification.&#xD;
&#xD;
          3. History and/or current evidence of clinically significant retinal disorder confirmed&#xD;
             by retinal examination.&#xD;
&#xD;
          4. A serious illness or medical condition(s)&#xD;
&#xD;
          5. Pregnant or breast-feeding female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Volker Wacheck, MD</last_name>
    <phone>609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Madappa Kundrandra, MD</last_name>
      <phone>480-440-7458</phone>
      <email>Madappa.kundranda@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Kundrandra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Robin R Kelly, MD</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sneha Nalla</last_name>
      <phone>415-353-7284</phone>
      <email>Sneha.Nalla@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Division of Hematology-Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Rosen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Center of Florida</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Yvonne Enriquez-Nunez</last_name>
      <phone>305-674-2625</phone>
      <email>yenrique@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Cusnir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Liao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Nilofer Azad, MD</last_name>
      <phone>410-614-1058</phone>
      <email>nazad2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Azad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Patricia Lynch, RN</last_name>
      <phone>617-643-0816</phone>
      <email>lynch.patricia2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Goyal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>GI Research Nursing</last_name>
      <phone>617-632-3000</phone>
      <email>DFCIGCCRNRS@partners.org</email>
    </contact>
    <investigator>
      <last_name>Cleary</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Ravi Chuda, MD</last_name>
      <phone>913-574-2350</phone>
      <email>rchuda@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Chuda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Funda Meric-Bernstam</last_name>
      <phone>713-794-1226</phone>
      <email>fmeric@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Meric-Bernstam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tracey N Pierce</last_name>
      <phone>206-606-7603</phone>
      <email>pierct@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholangiocarcinoma, CCA, FGFR2 Gene Rearrangements, TAS-120, Futibatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Futibatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

